| scholarly article | Q13442814 |
| P2093 | author name string | Kip A West | |
| Joell J Gills | |||
| Junji Tsurutani | |||
| Phillip A Dennis | |||
| Jacqueline Sayyah | |||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sirolimus | Q32089 |
| lung cancer | Q47912 | ||
| imatinib | Q177094 | ||
| chemotherapy | Q974135 | ||
| P304 | page(s) | 8423-8432 | |
| P577 | publication date | 2005-09-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy | |
| P478 | volume | 65 |
| Q24306139 | Achaete-scute homolog-1 linked to remodeling and preneoplasia of pulmonary epithelium |
| Q36427239 | Bioinformatics for cancer management in the post-genome era. |
| Q24323184 | Breast cancer-derived K172N, D301V mutations abolish Na+/H+ exchanger regulatory factor 1 inhibition of platelet-derived growth factor receptor signaling |
| Q54977984 | Bufalin induces apoptosis in human esophageal carcinoma ECA109 cells by inhibiting the activation of the mTOR/p70S6K pathway. |
| Q40059658 | Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia |
| Q38830266 | Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1. |
| Q40153829 | Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. |
| Q39020907 | Dendritic cells: In vitro culture in two- and three-dimensional collagen systems and expression of collagen receptors in tumors and atherosclerotic microenvironments. |
| Q39733170 | Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. |
| Q40330305 | ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase |
| Q36942696 | Effect of combination of rapamycin and cisplatin on human cervical carcinoma Hela cells |
| Q40064019 | Effects of collagen iv on cisplatin-induced apoptosis of non-small cell lung cancer cells |
| Q60047620 | Efficacy of Prednisolone in Generated Myotubes Derived From Fibroblasts of Duchenne Muscular Dystrophy Patients |
| Q43080122 | Expression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumors. |
| Q35632245 | Expression of phosphorylated mTOR and its clinical significances in small cell lung cancer |
| Q41859785 | Increased Resistance of Breast, Prostate, and Embryonic Carcinoma Cells against Herpes Simplex Virus in Three-Dimensional Cultures |
| Q43196142 | Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells |
| Q39905603 | Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide |
| Q33589931 | Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines |
| Q37076592 | Linifanib (ABT-869) Potentiates the Efficacy of Chemotherapeutic Agents through the Suppression of Receptor Tyrosine Kinase-Mediated AKT/mTOR Signaling Pathways in Gastric Cancer. |
| Q80130796 | Linking oncogenic pathways with therapeutic opportunities |
| Q92523787 | MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion |
| Q55110585 | Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models. |
| Q36512542 | Modulation of response to tumor therapies by the extracellular matrix |
| Q24606677 | Molecular biology of lung cancer |
| Q24610335 | Molecular biology of lung cancer: clinical implications |
| Q39146371 | NCAM polysialylation during adherence transitions: live cell monitoring using an antibody-mimetic EGFP-endosialidase and the viability dye DRAQ7. |
| Q31121212 | Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data. |
| Q37892341 | Novel strategies for the treatment of small-cell lung carcinoma |
| Q36142170 | Plumbagin suppresses epithelial to mesenchymal transition and stemness via inhibiting Nrf2-mediated signaling pathway in human tongue squamous cell carcinoma cells |
| Q37051667 | Possible mechanisms of disease development in tuberous sclerosis |
| Q35741627 | Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma |
| Q34881610 | Regulation of cytokine-induced prostanoid and nitric oxide synthesis by extracellular signal–regulated kinase 1/2 in lung epithelial cells |
| Q36844334 | Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment |
| Q40113117 | Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer |
| Q36843582 | Suppression of Nkx3.2 by phosphatidylinositol-3-kinase signaling regulates cartilage development by modulating chondrocyte hypertrophy |
| Q36302314 | Suppression of the GTPase-activating protein RGS10 increases Rheb-GTP and mTOR signaling in ovarian cancer cells |
| Q37033067 | Sustained activation of Akt and Erk1/2 is required for Coxiella burnetii antiapoptotic activity |
| Q35690750 | Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis. |
| Q39896250 | Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung |
| Q36054970 | Targeted therapies for lung cancer: clinical experience and novel agents |
| Q37741531 | Targeting the Mammalian Target of Rapamycin in Lung Cancer. |
| Q37135372 | The ERBB3 receptor in cancer and cancer gene therapy |
| Q39042894 | The Phosphatidylinositol 3-kinase/Akt Signaling Pathway in Neuroendocrine Tumors |
| Q38654867 | The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer. |
| Q49165125 | The Use of PET Imaging for Prognostic Integrin α2β1 Phenotyping to Detect Non-Small Cell Lung Cancer and Monitor Drug Resistance Responses |
| Q40165123 | The anticancer drug imatinib induces cellular autophagy. |
| Q28477884 | The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinoma |
| Q36609767 | Therapeutic resistance in lung cancer |
| Q28396304 | Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer |
| Q37462524 | Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy |
| Q37211707 | microRNA-199a is able to reverse cisplatin resistance in human ovarian cancer cells through the inhibition of mammalian target of rapamycin |
Search more.